U.S. Robotic Prosthetics and Orthotics Market

Market Outlook

The U.S. Robotic Prosthetics and Orthotics Market is projected to reach approximately USD 5.93 billion by 2032, expanding at a CAGR of 17.01% during the forecast period 2027–2032. The market was valued at USD 2.31 billion in 2026, following expansion from USD 1.52 billion in 2023 to USD 1.74 billion in 2024 and USD 2.02 billion in 2025. Values in this report are expressed in USD billions unless specifically identified as reimbursement, clinical or operating metrics.

Based on the market model used in this report, revenue is positioned to reach approximately USD 2.70 billion in 2027, USD 3.16 billion in 2028, USD 3.70 billion in 2029, USD 4.33 billion in 2030, USD 5.07 billion in 2031 and USD 5.93 billion by 2032. Growth is being driven by the transition from passive mechanical prostheses and conventional braces toward microprocessor-controlled knees, powered ankle-foot systems, multi-articulating myoelectric upper-limb devices, sensor-rich orthoses, wearable rehabilitation robotics and personal robotic exoskeletons.

The U.S. has an unusually favorable underlying clinical need profile for advanced prosthetic and orthotic technology. More than 5.6 million Americans are living with limb loss or limb difference, including more than 2.3 million people with limb loss and approximately 3.4 million with limb difference. Vascular disease and diabetes remain major contributors to lower-limb amputation, while trauma, cancer and congenital conditions create additional demand across upper- and lower-extremity prosthetic care. Peripheral artery disease alone affects approximately 6.5 million Americans aged 40 years and older, while diabetes affects roughly 38 million U.S. adults.

Robotic orthotics also address a wider neurological mobility population extending beyond amputees. More than 795,000 strokes occur annually in the United States, approximately 9.4 million U.S. adults have a history of stroke, and roughly 255,000 to 390,000 Americans are living with spinal cord injury, with around 18,000 new spinal cord injuries occurring annually. These populations create addressable opportunities for powered upper-extremity orthoses, gait-assist systems, robotic exoskeletons and sensor-enabled rehabilitation technologies.

A significant structural growth catalyst is the continuing evolution of U.S. reimbursement. Medicare coverage criteria were broadened in 2024 to permit qualifying K2 limited-community ambulators to access specified microprocessor-controlled prosthetic knees and compatible higher-function prosthetic feet. Separately, personal powered exoskeletons received a clearer Medicare reimbursement framework, with HCPCS K1007 classified within the brace benefit category and a national 2024 purchase payment benchmark of approximately USD 91,032. These policy developments materially expand the economic accessibility of high-value robotic mobility technologies.

Introduction

According to the U.S. Robotic Prosthetics and Orthotics Market Report, the sector is transitioning from a component-driven prosthetics industry into a connected mobility ecosystem built around mechatronics, embedded computing, sensing, powered actuation, adaptive control and increasingly intelligent human-machine interfaces.

For the purposes of this report, robotic prosthetics include electronically controlled or powered lower-limb prostheses, microprocessor knees, powered knees and ankle-foot systems, myoelectric and multi-articulating upper-limb prostheses, robotic hands and intelligent prosthetic components. Robotic orthotics include powered limb braces, neuromuscular assist orthoses, upper-extremity robotic support systems, gait-assist exoskeletons and personal or institutional wearable robots intended to augment movement.

Traditional passive prosthetic limbs, purely mechanical joints, non-powered off-the-shelf braces, conventional spinal orthoses, wheelchairs and general-purpose rehabilitation robots are excluded unless advanced electronics, powered assistance or adaptive robotic control is integral to the device.

This distinction matters commercially. Conventional prosthetics and orthotics are mature medical-device categories characterized by relatively predictable replacement cycles and payer-established coding structures. Robotic O&P systems operate under different economics. Their average selling prices are substantially higher, clinical qualification is more demanding, fitting and programming requirements are greater, reimbursement documentation is more complex, and the value proposition depends on measurable improvements in mobility, stability, energy expenditure, falls, independence or functional participation.

The U.S. market also has a highly specialized distribution structure. Certified prosthetist-orthotist practices remain central to device selection, fitting, training and longitudinal adjustment. Rehabilitation hospitals and academic medical centers play an important role in robotic exoskeleton adoption. The Department of Veterans Affairs is strategically important for advanced prosthetic access and has stated that it provides care to more than 45,000 Veterans with major limb loss. Manufacturers therefore compete not simply for a physician prescription, but for clinical acceptance among prosthetists, physiatrists, physical therapists, rehabilitation physicians, neurologists, orthopedic specialists, VA clinicians, payers and patients.

From 2027 through 2032, the most important commercial shift will be from electronically controlled assistance toward adaptive powered mobility. Devices capable of interpreting gait, muscle signals, limb position and terrain in real time will progressively separate premium robotic systems from conventional O&P products. This will increase the strategic value of software algorithms, sensors, motors, batteries, clinician programming interfaces and patient-facing applications.

Key Market Drivers: What’s Fueling the U.S. Robotic Prosthetics and Orthotics Market Boom?

The first major driver is the large and persistent U.S. population living with limb loss and limb difference. More than 2.3 million Americans are living with limb loss, creating a substantial installed population requiring replacement sockets, prosthetic components, knees, feet, hands and supporting clinical services over multiple years. Advanced systems capture a disproportionately high revenue opportunity because premium microprocessor knees, powered joints and multi-articulating hands carry substantially greater value per patient than basic mechanical devices.

The second driver is the burden of diabetes and vascular disease. Contemporary U.S. research indicates that vascular and diabetes-related disease represents the dominant source of major amputation procedures. This is strategically important because dysvascular amputees are frequently older, have multiple comorbidities and may be classified at lower functional levels than younger traumatic amputees. Historically, some advanced prosthetic technologies were concentrated among high-functioning K3 and K4 users. Broader access to selected microprocessor technologies for K2 users therefore increases the addressable Medicare population.

The third driver is reimbursement modernization. Effective September 1, 2024, lower-limb prosthetic policy revisions expanded eligibility for specified microprocessor-controlled knees, associated hydraulic or pneumatic components and compatible higher-level prosthetic feet among qualifying K2 beneficiaries. A K2 beneficiary is typically a limited-community ambulator capable of traversing low-level environmental barriers such as curbs, stairs or uneven surfaces. Opening advanced technology to this population represents an important expansion beyond historically narrower functional-level eligibility.

The fourth driver is growing acceptance of wearable robotics within neurological rehabilitation. Approximately 18,000 new spinal cord injuries occur annually in the U.S., while hundreds of thousands of people live with chronic SCI. Stroke creates an even larger neurological rehabilitation pool, with more than 795,000 events annually. These patient populations support demand for powered gait systems, upper-limb robotic orthoses and wearable assistive technologies used in rehabilitation centers or, increasingly, personal environments.

The fifth driver is the establishment of reimbursement pathways for powered exoskeletons. Medicare’s treatment of certain personal exoskeletons as orthotic braces represents a structural commercial change. The 2024 fee schedule benchmark for HCPCS K1007 reached roughly USD 91,032 for a covered personal powered bilateral hip-knee-ankle-foot system. That payment level demonstrates that the U.S. reimbursement framework can support sophisticated wearable robotics when medical necessity and benefit-category requirements are satisfied.

The sixth driver is the growing emphasis on fall reduction and safe community mobility. Microprocessor-controlled knees can detect gait phases and dynamically alter resistance. Newer devices incorporate stumble-recovery algorithms, variable cadence management, ramp and stair functions and standing assistance. For older or medically complex amputees, these functions have economic implications beyond mobility because falls can trigger fractures, hospitalization, rehabilitation and loss of independence.

The seventh driver is increased computational capability within wearable devices. Inertial measurement units, pressure sensors, torque sensing, EMG signal processing, embedded processors and smartphone connectivity are becoming standard differentiators in premium systems. These technologies allow the device to respond to changing movement patterns rather than operate through fixed mechanical resistance.

The eighth driver is growing interest in personalized control interfaces. Myoelectric upper-extremity prostheses can use electrical activity generated by residual muscles to control powered hands or elbows. Pattern-recognition systems can interpret more complex muscle-signal combinations, while research programs are advancing targeted muscle reinnervation, peripheral nerve interfaces and sensory-feedback technologies. The commercial significance is that future prostheses will compete increasingly on the quality of control rather than simply mechanical design.

The ninth driver is U.S. Veterans Health Administration adoption. VA provides prosthetic care to more than 45,000 Veterans with major limb loss and has an established history of supporting high-function prosthetic technologies and powered exoskeletons for eligible patients. The VA is therefore an important early-adoption channel and a source of clinical experience for premium prosthetic systems.

The tenth driver is patient expectation. Younger traumatic amputees, working-age users and increasingly technology-aware older adults expect their prostheses to perform across variable terrain, stairs, work environments and recreational situations. Expectations are also rising in upper-extremity prosthetics, where users increasingly evaluate grip selection, speed, weight, durability, water resistance, battery endurance and intuitive control.

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in robotic prosthetics is moving from resistance control toward active power generation. Traditional microprocessor knees primarily regulate hydraulic resistance. Powered knees add motors capable of producing movement, potentially assisting sit-to-stand transitions, stair ascent and forward progression. Össur’s POWER KNEE represents an important example of this transition toward active bionic assistance.

Microprocessor knee technology itself continues to improve. Modern systems monitor gait continuously and adjust swing and stance behavior in real time. Premium designs incorporate stumble recovery, incline and decline recognition, multiple activity modes, improved weather resistance, longer battery life and smartphone-based configuration. Ottobock reports more than 100,000 fittings across its microprocessor-knee experience base, illustrating how advanced electronically controlled knees have moved beyond experimental technology into an established prosthetic category.

Upper-limb prosthetics are advancing through lighter multi-grip hands, improved EMG control and more accessible fabrication. Products such as the Hero Arm illustrate the migration of multi-grip myoelectric prosthetics into broader U.S. clinical networks. Open Bionics reports U.S. availability through hundreds of clinical locations, expanding access beyond a small number of academic prosthetic centers.

Wearable orthotic robotics are also moving from institutional rehabilitation toward personal use. Early powered exoskeletons typically required structured clinical environments and significant supervision. New product development is targeting better balance, easier donning, smaller form factors and more practical daily-living functionality. FDA clearance of Wandercraft’s Eve personal self-balancing exoskeleton in August 2026 represents an important milestone because it extends powered upright mobility toward eligible wheelchair users outside conventional rehabilitation sessions.

Regulatory progress is expanding institutional competition as well. ReWalk 7 received FDA 510(k) clearance in March 2025, while Wandercraft’s Atalante X received FDA clearance in October 2025. The expansion of cleared systems means U.S. rehabilitation providers can increasingly compare platforms based on training time, patient eligibility, clinical throughput, balance assistance, therapist burden and economic utilization rather than simply technology availability.

Sensor fusion will be another critical competitive area. Combining joint-angle data, accelerometry, gyroscopes, pressure information and motor torque enables a robotic device to infer what the user is attempting to do. Future differentiation will increasingly come from how accurately and rapidly the device interprets those signals.

Battery and actuator technology remains equally important. Powered systems must generate useful torque without becoming too heavy, noisy or thermally inefficient. Improvements in battery energy density, motor control and lightweight structural materials can therefore directly increase wear time and patient acceptance.

Manufacturers are also building digital infrastructure around the hardware. Clinician programming software, remote diagnostics, utilization data and patient applications can reduce service burden and improve fitting efficiency. Over time, connected-device data may also strengthen reimbursement submissions by documenting actual use and functional improvement.

Segmentation Insights

The U.S. Robotic Prosthetics and Orthotics Market is segmented on the basis of product category, technology, application, end user, payer channel and geography.

By Product Category

Microprocessor-controlled lower-limb prostheses represent the largest product category, accounting for approximately 39.0% of 2026 market revenue, equivalent to around USD 0.90 billion. This category includes electronically controlled prosthetic knees and associated intelligent components. Growth is supported by expanded K2 reimbursement eligibility, established demand among K3 and K4 ambulators and increasing emphasis on stability and stumble recovery. The category is projected to maintain double-digit growth through 2032 even as fully powered systems grow faster.
Robotic and myoelectric upper-limb prostheses generated approximately 21.2% of 2026 revenue, or around USD 0.49 billion. Multi-articulating hands, powered elbows, myoelectric terminal devices and integrated pattern-recognition control systems form the core of this subsegment. The U.S. addressable population includes traumatic amputees, Veterans and people with congenital upper-limb differences. Greater availability through distributed O&P networks is helping advanced upper-limb systems move beyond specialized academic centers.
Powered exoskeletons and robotic orthoses accounted for approximately 18.6% of 2026 revenue, corresponding to roughly USD 0.43 billion. This is the fastest-growing product group and includes institutional gait-training exoskeletons, personal mobility exoskeletons, powered upper-extremity orthoses and motor-assisted limb braces. Growth through 2032 is expected to exceed the overall market CAGR because of clearer reimbursement pathways, FDA-cleared product expansion and a large neurological rehabilitation population.
Powered ankle-foot and actively assisted prosthetic systems represented approximately 12.1% of 2026 market revenue, or around USD 0.28 billion. These devices attempt to restore ankle power, improve rollover, adapt to slopes or reduce compensatory movement. Adoption remains more selective than microprocessor-knee adoption because reimbursement and clinical qualification differ across technologies, but powered ankle and knee-ankle integration remains one of the highest-value innovation opportunities.
Intelligent controls, embedded components and robotic interface technologies accounted for the remaining 9.1%, or approximately USD 0.21 billion. The segment includes advanced sensors, control electronics, pattern-recognition interfaces and integrated digital technologies sold as part of an advanced prosthetic or orthotic system. Growth will be driven by the transition from hardware differentiation toward adaptive control.

By Technology

Microprocessor-adaptive control technology represented approximately 34.6% of 2026 revenue, or around USD 0.80 billion. The category is commercially mature within premium lower-limb prosthetics but continues to expand as eligible patient populations widen. Real-time gait adaptation and stumble-response functionality are becoming expected characteristics rather than optional premium features.
Myoelectric and EMG-based control systems accounted for roughly 22.5%, equivalent to approximately USD 0.52 billion. These systems dominate advanced upper-limb robotic prosthetics and are increasingly paired with multi-grip hands, pattern-recognition software and app-based configuration. Clinical success depends heavily on socket fit, electrode positioning, training and signal quality.
Powered electromechanical actuation accounted for approximately 19.9%, or around USD 0.46 billion. Powered knees, exoskeleton joints and motorized orthoses form the core of this category. It is projected to be one of the fastest-growing technologies through 2032 because powered systems can add energy rather than merely control resistance.
Sensor-fusion and AI-enabled adaptive systems represented about 13.4% of 2026 market revenue, or approximately USD 0.31 billion. These platforms combine multiple sensor inputs to classify terrain, gait phases or user intent. The segment is expected to grow well above the market average as adaptive algorithms become central to product differentiation.
Hybrid biofeedback, neuromuscular and emerging neural-interface technologies represented approximately 9.5%, or around USD 0.22 billion. Commercial availability is smaller, but the segment is strategically important because future devices may increasingly integrate biological signals with robotic assistance.

By Application

Lower-limb amputation mobility is the largest application and accounted for approximately 46.3% of 2026 revenue, equivalent to around USD 1.07 billion. The scale reflects the high prevalence of lower-extremity amputation, particularly among patients affected by diabetes and vascular disease. Microprocessor knees, powered knees, adaptive feet and intelligent ankle systems dominate spending.
Upper-limb functional replacement represented approximately 20.3%, or USD 0.47 billion. Growth is being driven by improved myoelectric control, lighter hands, pediatric access, multi-grip functionality and wider clinical availability. This application remains smaller by patient volume but attracts high per-device revenue.
Neurological mobility and rehabilitation accounted for approximately 17.7%, or USD 0.41 billion. Stroke, spinal cord injury and other neurological conditions provide a large clinical pool for robotic gait systems and powered orthoses. More than 795,000 annual U.S. strokes and approximately 18,000 annual spinal cord injuries underline the scale of potential need, although only a subset of patients meet device-specific eligibility criteria.
Musculoskeletal and motor-impairment assistance represented approximately 9.1%, or around USD 0.21 billion. This segment includes powered orthoses designed to assist weakened limbs where the anatomy remains present but voluntary movement is impaired.
Pediatric and congenital limb-difference applications represented approximately 6.5%, or around USD 0.15 billion. The segment is commercially smaller but strategically attractive because pediatric users may require multiple replacements as they grow. Weight, socket adaptability, durability and payer authorization are particularly important purchasing considerations.

By End User

Prosthetic and orthotic clinics are the largest end-user category, accounting for approximately 42.4% of 2026 market revenue, or around USD 0.98 billion. Their dominance reflects the specialized fitting, alignment, coding, documentation and programming required for advanced devices. Manufacturers that secure relationships with large O&P networks and independent certified practitioners gain significant influence over product selection.
Rehabilitation hospitals and integrated health systems represented approximately 22.1%, or USD 0.51 billion. These institutions are especially important for powered exoskeletons, neurological rehabilitation and initial gait training. Academic centers are also influential in clinical research and technology assessment.
VA and military healthcare channels accounted for approximately 13.0%, equivalent to roughly USD 0.30 billion. VA’s care infrastructure for more than 45,000 Veterans with major limb loss makes it an important premium prosthetic channel. Veterans with spinal cord injury also represent a meaningful exoskeleton user population.
Home and personal-use mobility accounted for approximately 14.7%, or USD 0.34 billion. This segment is expected to expand rapidly as personal exoskeleton reimbursement matures and robotic devices become easier to operate outside institutional settings.
Research institutions and specialty neurological centers represented approximately 7.8%, equivalent to USD 0.18 billion. Although smaller commercially, these centers strongly influence clinical protocols, evidence generation and early adoption.

By Payer and Procurement Channel

Commercial insurance represented approximately 31.2% of 2026 market revenue, or around USD 0.72 billion. Commercial payers are important for working-age traumatic amputees, congenital limb difference and employer-sponsored beneficiaries. Prior authorization and medical-necessity documentation remain substantial access barriers.
Medicare, including Medicare Advantage influence, represented approximately 28.1%, or around USD 0.65 billion. Medicare is strategically important because older adults account for a substantial share of dysvascular lower-limb loss. The 2024 expansion of qualifying K2 access to microprocessor knee technology materially improves long-term adoption potential.
VA, Department of Defense and other federal channels accounted for approximately 13.0%, or USD 0.30 billion. These channels can support high-value technologies when clinical eligibility is established and are particularly relevant to traumatic limb loss.
Medicaid, workers’ compensation and other public channels accounted for approximately 14.7%, or around USD 0.34 billion. Coverage varies significantly by state and benefit structure, making market access more fragmented than Medicare.
Self-pay, charitable funding and other payment sources represented approximately 13.0%, or around USD 0.30 billion. This category remains important in pediatric and upper-limb prosthetics where benefit limits or authorization delays can create funding gaps.

Regional Insights: Where the Market is Growing Fastest

The U.S. Robotic Prosthetics and Orthotics Market is geographically segmented into the South, West, Northeast and Midwest. Geographic performance differs based on population, diabetes burden, aging demographics, trauma incidence, spinal cord injury rehabilitation capacity, Medicare exposure, VA facilities, academic rehabilitation programs, O&P practitioner density and private payer mix.

The South represents the largest regional market, while the West is expected to record the fastest growth through 2032. The Northeast remains highly attractive for premium clinical adoption and academic innovation, while the Midwest provides a substantial installed O&P and rehabilitation base.

South

The South accounted for approximately USD 0.81 billion in 2026, representing about 35.1% of the national market. Revenue is projected to approach USD 2.12 billion by 2032, corresponding to a regional CAGR of approximately 17.4%.

The region encompasses Texas, Florida, Georgia, North Carolina, South Carolina, Virginia, West Virginia, Maryland, Delaware, Kentucky, Tennessee, Alabama, Mississippi, Arkansas, Louisiana, Oklahoma and the District of Columbia. Its leadership reflects population scale, diabetes and vascular-disease burden, large Medicare populations, expanding metropolitan health systems and significant VA presence.

Texas is one of the largest state opportunities in the national market. Houston, Dallas-Fort Worth, Austin and San Antonio contain major health systems, rehabilitation providers, VA facilities and O&P practices. Texas benefits from both a large working-age population and a substantial diabetes-related limb-loss burden. Within the report’s state-level model, Texas accounts for slightly more than 8% of national robotic O&P revenue.

Florida is another major market because of its older population and high Medicare exposure. Lower-limb microprocessor systems are particularly relevant because older dysvascular amputees increasingly fall within the functional profiles targeted by K2-oriented technologies. Florida represents approximately 7% of national market revenue.

North Carolina, Georgia, Virginia and Tennessee form an important secondary growth cluster. Research hospitals, rehabilitation systems and rapidly growing metropolitan populations support demand for advanced prosthetics and rehabilitation robotics. North Carolina also benefits from substantial medical-device and life-sciences activity around the Research Triangle.

Maryland and the District of Columbia are important because of federal healthcare, military medicine and proximity to major research institutions. Virginia adds a substantial military and Veteran population, strengthening demand for traumatic-amputation prosthetic technologies.

Alabama, Mississippi, Louisiana, Arkansas, Kentucky, Oklahoma and West Virginia have high chronic-disease burdens that create significant clinical need for lower-limb prosthetic care. The commercial challenge is that rural access, specialist density and payer mix can limit penetration of premium robotic systems. Manufacturers capable of supporting regional O&P practices with training, reimbursement documentation and remote programming can address this gap.

The South should remain the largest regional market through 2032 because demographic and disease-burden factors create a persistent stream of new prosthetic users, while reimbursement expansion increases the portion eligible for advanced technology.

West

The West represented approximately USD 0.59 billion in 2026, or around 25.5% of national revenue, and is projected to reach roughly USD 1.64 billion by 2032. Its approximately 18.6% CAGR makes it the fastest-growing U.S. region.

The region includes California, Washington, Oregon, Arizona, Nevada, Colorado, Utah, New Mexico, Idaho, Montana, Wyoming, Alaska and Hawaii.

California is the largest state market in the West and the leading individual U.S. state for robotic prosthetics and orthotics, representing approximately 11%–12% of national revenue. Its leadership reflects population scale, leading rehabilitation hospitals, major universities, extensive venture-backed medtech activity and strong adoption of digital and robotic healthcare technologies.

California is particularly important for advanced upper-limb prosthetics, software-enabled control systems and experimental neural-interface technologies. Academic programs and specialty rehabilitation centers frequently participate in research that influences subsequent national adoption.

Arizona and Nevada are attractive because of rapid population growth and aging demographics. Both states have expanding orthopedic, rehabilitation and O&P infrastructure. Arizona’s retiree population creates increasing demand for lower-limb prosthetic care, while Phoenix is becoming an important healthcare hub.

Washington, Oregon, Colorado and Utah have comparatively strong adoption of technology-enabled healthcare. Seattle, Portland, Denver and Salt Lake City contain integrated health systems and rehabilitation networks capable of evaluating premium robotic systems. Washington and Colorado are especially important for innovation-oriented rehabilitation programs.

New Mexico, Idaho, Montana, Wyoming and Alaska are smaller markets but highlight the need for remote support. Patients may travel substantial distances for specialist prosthetic fitting. Connected diagnostics and remote adjustment therefore have higher workflow value than in dense metropolitan regions.

Hawaii is relatively small by population but has unique rehabilitation logistics and a significant federal and military healthcare presence.

The West’s long-term advantage is the interaction between clinical adoption and technology development. Artificial intelligence, robotics, sensors, cloud-connected monitoring and venture financing are more closely integrated in this region than in most other U.S. markets.

Northeast

The Northeast accounted for approximately USD 0.51 billion in 2026, or around 22.1% of the national market, and is projected to reach approximately USD 1.24 billion by 2032, corresponding to a CAGR of roughly 16.0%.

The region includes New York, Pennsylvania, New Jersey, Massachusetts, Connecticut, Rhode Island, Maine, New Hampshire and Vermont.

New York is the largest Northeast market and represents approximately 6% of national robotic O&P revenue. New York City and the broader state contain large rehabilitation systems, academic medical centers, VA facilities and specialized prosthetics practices. The combination supports high-value upper-limb, lower-limb and exoskeleton adoption.

Massachusetts has outsized strategic influence despite its smaller population. Boston’s concentration of robotics, engineering, medical research and rehabilitation institutions makes the state important for device development, clinical evaluation and early adoption. Myomo, a U.S. wearable medical robotics company, is headquartered in Massachusetts and has built commercial activity around the MyoPro powered upper-extremity orthosis.

Pennsylvania and New Jersey provide large patient populations and mature rehabilitation infrastructure. Pennsylvania has major clinical hubs around Philadelphia and Pittsburgh, while New Jersey benefits from proximity to New York and a strong medical-device ecosystem.

Connecticut, Rhode Island, Maine, New Hampshire and Vermont are smaller state markets, but aging demographics support demand for lower-extremity mobility solutions. The principal commercial limitation is lower absolute procedure volume outside major metropolitan referral centers.

Northeast purchasing behavior is comparatively evidence-driven. Health systems and academic institutions often require formal clinical outcomes, rehabilitation protocols and payer support before broad adoption. This can slow initial uptake but creates strong reference centers once technologies demonstrate value.

Midwest

The Midwest represented approximately USD 0.40 billion in 2026, or around 17.3% of national revenue, and is projected to reach approximately USD 0.93 billion by 2032, reflecting a CAGR of roughly 15.1%.

The region includes Illinois, Ohio, Michigan, Indiana, Wisconsin, Minnesota, Iowa, Missouri, Kansas, Nebraska, North Dakota and South Dakota.

Illinois is the largest Midwest state market, driven by Chicago’s extensive academic, rehabilitation and O&P provider ecosystem. The state accounts for approximately 3%–4% of national robotic O&P demand.

Ohio is an important rehabilitation and prosthetic-care market with strong health systems in Cleveland, Columbus and Cincinnati. Michigan combines major hospital networks with a large industrial workforce and meaningful traumatic and dysvascular prosthetic demand.

Minnesota is strategically important because of its longstanding medical-device ecosystem and advanced rehabilitation infrastructure. The state’s clinical culture supports early evaluation of sophisticated mobility technologies.

Indiana, Wisconsin and Missouri provide stable demand through established regional referral systems. Iowa, Kansas, Nebraska, North Dakota and South Dakota are smaller but important markets for lower-limb prosthetic care, particularly where patients depend on regional O&P centers.

The Midwest is unlikely to outgrow the West or South because population growth is slower, but it remains commercially attractive for manufacturers capable of demonstrating durability, clinical value and reimbursement reliability.

Key Market Players

The U.S. Robotic Prosthetics and Orthotics competitive landscape combines established prosthetics manufacturers, rehabilitation-robotics companies, O&P service networks and emerging bionic-device specialists.

Large prosthetics companies have advantages in payer relationships, practitioner education, established component portfolios and national distribution. Smaller robotic companies can gain share through differentiated powered assistance, novel control systems or specialized neurological applications.

Competition is shifting from individual components toward integrated ecosystems combining the physical device, software, fitting tools, rehabilitation protocols, patient training, clinician education and reimbursement support.

Some of the key players operating in the U.S. Robotic Prosthetics and Orthotics Market are:

Ottobock
Össur
Blatchford
Hanger, Inc.
Fillauer
WillowWood Global
Lifeward
Ekso Bionics Holdings
Wandercraft
Myomo
Open Bionics
PSYONIC
Mobius Bionics
CIONIC
Unlimited Tomorrow

Ottobock and Össur hold particularly strong positions in advanced lower-limb prosthetics because of established microprocessor and powered technologies, extensive practitioner relationships and large installed user bases. Hanger is strategically important on the service side because clinical networks influence product selection and reimbursement execution.

Lifeward, Ekso Bionics and Wandercraft compete within wearable robotic mobility and exoskeleton applications. Myomo occupies a distinctive position in powered upper-extremity orthotics. Open Bionics, PSYONIC, Mobius Bionics and Unlimited Tomorrow increase competition in advanced upper-limb prosthetics through multi-articulating hands, myoelectric control and alternative manufacturing models.

Competitive success through 2032 will depend on clinical evidence, payer access, FDA clearance, practitioner training, service infrastructure, component reliability, battery life, device weight and measurable functional outcomes.

Recent Developments

The most commercially important development affecting the U.S. lower-limb prosthetic market was the September 2024 expansion of Medicare coverage criteria for specified advanced prosthetic knees and feet among qualifying K2 beneficiaries. Technologies previously associated primarily with higher-function K3 and K4 ambulators can now reach a broader limited-community-ambulator population when coverage conditions are met.

Medicare also created a clearer economic pathway for personal powered exoskeletons. HCPCS K1007 covers a powered bilateral hip-knee-ankle-foot device incorporating motors, microprocessors and sensors. The 2024 national Medicare purchase fee schedule amount was approximately USD 91,032, creating a meaningful reimbursement benchmark for advanced personal exoskeleton systems.

In March 2025, Lifeward’s ReWalk 7 Personal Exoskeleton received FDA 510(k) clearance. The development strengthens competition in personal robotic mobility and provides another regulatory milestone for powered exoskeleton technology.

In October 2025, the FDA cleared Wandercraft’s Atalante X powered exoskeleton. The clearance expanded Wandercraft’s ability to compete in the U.S. institutional rehabilitation market.

Myomo continued to commercialize its MyoPro powered upper-extremity orthosis through the U.S. O&P channel. The company reported approximately USD 0.041 billion in 2025 revenue and trained more than 300 certified prosthetist-orthotists by the end of the first quarter of 2025, demonstrating how robotic orthotic manufacturers are increasingly using traditional O&P practitioners as a scalable distribution network.

In August 2026, Wandercraft announced FDA clearance of Eve, a personal self-balancing exoskeleton intended for eligible adults with spinal cord injury. The product represents a potentially important change in personal mobility robotics because self-balancing technology reduces dependence on the conventional crutch-supported exoskeleton architecture.

Upper-limb competition is also intensifying. Manufacturers are introducing lighter multi-articulating hands, wireless myoelectric sensors, app-based grip customization and more modular sockets. Open Bionics has expanded the U.S. clinical availability of the Hero Arm and related technologies, including access within VA-linked care pathways.

The cumulative effect of these developments is a market moving away from isolated premium devices toward a broader reimbursement-supported robotic mobility category.

Conclusion

The U.S. Robotic Prosthetics and Orthotics Market Size & Share is positioned for rapid expansion from USD 2.31 billion in 2026 to approximately USD 5.93 billion by 2032, representing a 17.01% CAGR during 2027–2032.

The market is being transformed by three structural forces. First, the U.S. has a large and growing population requiring advanced mobility support, including more than 2.3 million people with limb loss, millions with limb difference, hundreds of thousands living with spinal cord injury and a substantial post-stroke rehabilitation population. Second, reimbursement pathways are expanding for technologies such as microprocessor knees and powered exoskeletons. Third, device technology is moving rapidly from passive mechanics toward adaptive sensing, intelligent control and active power generation.

Lower-limb robotic prosthetics will remain the largest revenue pool, but wearable exoskeletons and powered orthoses are expected to show the strongest growth. Myoelectric upper-limb systems will remain an important premium category as grip functionality, pattern recognition and affordability improve.

Geographically, the South will remain the largest market, reflecting population scale, diabetes burden and Medicare exposure. The West is expected to grow fastest because of strong technology adoption, robotics development and innovation-oriented health systems. The Northeast will remain influential in clinical evidence generation and premium adoption, while the Midwest will provide a stable base of established prosthetic and rehabilitation demand.

For manufacturers, the decisive competitive issue will not be robotics capability alone. Commercial leadership will require technologies that fit U.S. reimbursement rules, deliver clinically measurable function, can be supported by prosthetists and therapists, and generate sufficient evidence to justify premium pricing.

For investors, healthcare providers, manufacturers and market-access teams, the most attractive opportunities through 2032 are expected to concentrate in expanded K2 microprocessor adoption, actively powered lower-limb systems, personal self-balancing exoskeletons, multi-articulating upper-limb prostheses, powered neurological orthoses and software that improves human-machine control.

The companies that establish the strongest combination of device performance, clinical evidence, payer access, practitioner training and longitudinal patient support will be best positioned to capture the next phase of U.S. robotic prosthetic and orthotic growth.